Related Experiment Video
Updated: Jun 6, 2026
07:58
Cell-Free DNA Integrity Analysis in Urine Samples
Published on: January 5, 2017
[Plasma E-cadherin levels in urinary bladder cancer: does it improve risk stratification?]
T Szarvas1, F Hoffmann, M Becker
1Klinik für Urologie, Uroonkologie und Kinderurologie, Universitätsklinikum der Universität Duisburg-Essen, Hufelandstraße 55, 45147 Essen, Deutschland.
Der Urologe. Ausg. A
|December 15, 2010
Summary
Soluble E-cadherin levels are elevated in bladder cancer patients but do not predict disease progression or survival. New molecular markers are needed to identify high-risk patients after surgery.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Context:
- Urinary bladder cancer is a heterogeneous disease with poor prognosis for muscle-invasive cases.
- Metastatic progression post-surgery is a primary cause of mortality.
- Existing clinicopathological features offer limited predictive value for disease progression.
Purpose:
- To investigate the correlation between plasma E-cadherin levels and bladder cancer progression.
- To assess the potential of soluble E-cadherin as a prognostic marker in bladder cancer patients.
Summary:
- Plasma E-cadherin concentrations were significantly higher in bladder cancer patients compared to controls.
- E-cadherin levels did not significantly correlate with tumor stage, grade, or lymph node status.
- Plasma E-cadherin levels were unable to predict disease-specific or metastasis-free survival.
Impact:
- Soluble E-cadherin is not a reliable prognostic marker for bladder cancer.
- Highlights the need for external validation of prognostic markers.
- Emphasizes the urgent requirement for novel molecular markers to guide therapy decisions in high-risk patients post-cystectomy.
